tradmap

AMPH Financials Amphastar Pharmaceuticals, Inc.

14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 15.5% per year over the past 5 years.
  • Net income has grown faster than revenue (133.8% vs 15.5% per year).
  • Operating margin has expanded, at 19.5% in the latest year.
  • Free cash flow has grown 38.9% per year over the past 5 years.

Financial health

  • Total debt ($620M) exceeds cash ($170M); net debt is $450M.
  • Total debt has grown faster than revenue (68.3% vs 15.5% per year).
  • Operating income covered interest expense 5.5× in the latest year.
  • Total debt is 4.4× EBITDA.
Revenue & net income
-$11M $361M $732M $0 2012 2014 2016 2018 2020 2022 2024
RevenueNet income
Margins (gross / operating / net)
-3% 26% 54% 0% 2012 2014 2016 2018 2020 2022 2024
GrossOperatingNet
Free cash flow (CFO − capex)
-$9M $82M $172M $0 2012 2014 2016 2018 2020 2022 2024
Free cash flow
Cash vs total debt
$0 $310M $620M 2012 2014 2016 2018 2020 2022 2024
CashTotal debt
Cash flow: operating / investing / financing
-$649M -$98M $454M $0 2012 2014 2016 2018 2020 2022 2024
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 $720M $98M 49.5% 19.5% $121M $620M $170M
2024 $732M $160M 51.1% 28.1% $172M $614M $152M
2023 $644M $138M 54.5% 30.6% $145M $603M $144M
2022 $499M $91M 49.9% 21.5% $65M $77M $156M
2021 $438M $62M 45.6% 16.0% $71M $78M $126M
2020 $350M $1M 41.0% 3.1% $23M $46M $93M
2019 $322M $49M 40.9% -0.0% $207000 $46M $74M
2018 $295M -$6M 36.3% -2.9% -$9M $49M $86M
2017 $240M $4M 37.7% -0.5% $4M $46M $66M
2016 $255M $10M 40.8% 6.0% $17M $36M $72M
2015 — -$3M — — -$5M $40M $66M
2014 — -$11M — — — $43M $68M
2013 — $12M — — — — $54M
2012 — $18M — — — — $50M

Valuation over time

How the market has priced AMPH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 14.9 29.9 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/E
Price / sales (P/S)
0.0 2.7 5.5 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/S

Frequently asked questions

Is AMPH growing its revenue and profit?

Over the past 5 years, Amphastar Pharmaceuticals, Inc.'s revenue has grown 15.5% per year, and net income grown 133.8% per year. These are computed facts, not advice.

How much debt does AMPH have?

As of FY2025, Amphastar Pharmaceuticals, Inc. reported $620M of total debt against $170M of cash; operating income covered interest expense 5.5×.

What is AMPH's profit margin?

In FY2025, gross margin was 49.5%, operating margin 19.5%, and net margin 13.6%.

What is AMPH's P/E ratio?

As of Jun '26, Amphastar Pharmaceuticals, Inc. traded at a price-to-earnings ratio of about 9.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.